Related Experiment Video
Updated: Aug 2, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
Blood pressure surveillance in cancer patients treated with immune checkpoint inhibitors
Sean Tan1,2, Ella Spear3, Nikhita Sane3
1Victorian Heart Institute, Monash University, Melbourne, VIC, Australia. Sean.Tan@monash.edu.
Abstract:
Immune checkpoint inhibitors (ICI) are cancer therapies that have been associated with increased risk of atherosclerotic cardiovascular disease (ASCVD). Blood pressure (BP) measurements are routinely performed during day oncology center visits for administration of ICI therapy but are often not assessed temporally to screen and monitor hypertension, which could independently increase the risk of ASCVD in cancer survivorship. This study reports the feasibility of using serial BP measurements from routine visits to day oncology center to diagnose and monitor hypertension control in cancer patients receiving ICIs.
More Related Videos
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
Related Concept Videos
Pre-Procedural Guidelines for Assessing Blood Pressure
Measurement of Blood Pressure
Errors occurring during blood pressure monitoring
Several factors...
Hypertension III: Clinical Manifestations and Diagnostic Studies
Special considerations while measuring blood pressure
Monitoring Both Arms:
Monitoring BP in both arms during the initial assessment is advisable, as the systolic value may differ by five to ten mm Hg between arms. For subsequent BP assessments, use the arm with the higher reading.
Tumor Immunotherapy